IGC
Price
$0.41
Change
+$0.03 (+7.89%)
Updated
Oct 24 closing price
Capitalization
37.41M
17 days until earnings call
Intraday Buy/Sell Signals
PPTDF
Price
$11.10
Change
-$0.71 (-6.01%)
Updated
Sep 29 closing price
Capitalization
1.38B
Intraday Buy/Sell Signals
Interact to see
Advertisement

IGC vs PPTDF

Header iconIGC vs PPTDF Comparison
Open Charts IGC vs PPTDFBanner chart's image
IGC Pharma
Price$0.41
Change+$0.03 (+7.89%)
Volume$2.38M
Capitalization37.41M
Peptidream
Price$11.10
Change-$0.71 (-6.01%)
Volume$300
Capitalization1.38B
IGC vs PPTDF Comparison Chart in %
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PPTDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IGC vs. PPTDF commentary
Oct 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGC is a Hold and PPTDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 26, 2025
Stock price -- (IGC: $0.41 vs. PPTDF: $11.10)
Brand notoriety: IGC and PPTDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IGC: 234% vs. PPTDF: 28%
Market capitalization -- IGC: $37.41M vs. PPTDF: $1.38B
IGC [@Biotechnology] is valued at $37.41M. PPTDF’s [@Biotechnology] market capitalization is $1.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IGC’s FA Score shows that 0 FA rating(s) are green whilePPTDF’s FA Score has 0 green FA rating(s).

  • IGC’s FA Score: 0 green, 5 red.
  • PPTDF’s FA Score: 0 green, 5 red.
According to our system of comparison, IGC is a better buy in the long-term than PPTDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IGC’s TA Score shows that 5 TA indicator(s) are bullish while PPTDF’s TA Score has 2 bullish TA indicator(s).

  • IGC’s TA Score: 5 bullish, 3 bearish.
  • PPTDF’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, IGC is a better buy in the short-term than PPTDF.

Price Growth

IGC (@Biotechnology) experienced а +1.85% price change this week, while PPTDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.

Reported Earning Dates

IGC is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+0.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PPTDF($1.38B) has a higher market cap than IGC($37.4M). IGC YTD gains are higher at: 21.071 vs. PPTDF (-37.826). IGC has higher annual earnings (EBITDA): -6.36M vs. PPTDF (-3.66B). PPTDF has more cash in the bank: 33.3B vs. IGC (454K). IGC has less debt than PPTDF: IGC (202K) vs PPTDF (18.3B). PPTDF has higher revenues than IGC: PPTDF (19.1B) vs IGC (1.33M).
IGCPPTDFIGC / PPTDF
Capitalization37.4M1.38B3%
EBITDA-6.36M-3.66B0%
Gain YTD21.071-37.826-56%
P/E RatioN/A14.62-
Revenue1.33M19.1B0%
Total Cash454K33.3B0%
Total Debt202K18.3B0%
FUNDAMENTALS RATINGS
IGC vs PPTDF: Fundamental Ratings
IGC
PPTDF
OUTLOOK RATING
1..100
7050
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4782
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IGC's Valuation (41) in the Biotechnology industry is somewhat better than the same rating for PPTDF (87) in the null industry. This means that IGC’s stock grew somewhat faster than PPTDF’s over the last 12 months.

IGC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PPTDF (100) in the null industry. This means that IGC’s stock grew similarly to PPTDF’s over the last 12 months.

IGC's SMR Rating (100) in the Biotechnology industry is in the same range as PPTDF (100) in the null industry. This means that IGC’s stock grew similarly to PPTDF’s over the last 12 months.

IGC's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for PPTDF (82) in the null industry. This means that IGC’s stock grew somewhat faster than PPTDF’s over the last 12 months.

IGC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PPTDF (100) in the null industry. This means that IGC’s stock grew similarly to PPTDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IGCPPTDF
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
43%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
26%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
41%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
28%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 18 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
39%
View a ticker or compare two or three
Interact to see
Advertisement
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PPTDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AINTX18.260.14
+0.77%
Ariel International Investor
IEDCX12.140.09
+0.75%
Voya Large Cap Value C
AIERX23.810.11
+0.46%
Invesco EQV International Equity R
ILVBX10.950.04
+0.37%
Columbia Integrated Large Cap Val A
PRAFX17.30-0.01
-0.06%
T. Rowe Price Real Assets

IGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGC has been loosely correlated with TECX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if IGC jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
+7.90%
TECX - IGC
49%
Loosely correlated
-1.38%
ARTL - IGC
32%
Poorly correlated
-0.88%
ANVS - IGC
30%
Poorly correlated
+1.49%
MRNA - IGC
29%
Poorly correlated
+1.87%
KZR - IGC
28%
Poorly correlated
+0.16%
More

PPTDF and

Correlation & Price change

A.I.dvisor tells us that PPTDF and HOTH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PPTDF and HOTH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PPTDF
1D Price
Change %
PPTDF100%
N/A
HOTH - PPTDF
31%
Poorly correlated
+0.74%
BGMS - PPTDF
28%
Poorly correlated
-5.15%
IGC - PPTDF
22%
Poorly correlated
+7.90%
LABFF - PPTDF
22%
Poorly correlated
N/A
CPMV - PPTDF
21%
Poorly correlated
+4.62%
More